ELAN — Elanco Animal Health Incorporated stock price, charts and financials

QT55Elanco Animal Health Incorporated

Elanco Animal Health Incorporated (NYSE: ELAN) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
22.74
-0.12-0.52%
ELANQT55Elanco Animal Health Incorporated·NYSE
22.74-0.52%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.40Insider Own1.14%Shs Outstand499.45MPerf Week-0.52%
Market Cap11.36BForward P/E17.77EPS next Y1.28Insider Trans1.28%Shs Float494.82MPerf Month-3.81%
Enterprise Value14.75BPEG-EPS next Q0.20Inst Own-Short Float6.25%Perf Quarter-2.78%
Income-199.00MP/S2.26EPS this Y384.30%Inst Trans-Short Ratio5.12Perf Half Y-8.42%
Sales5.02BP/B1.72EPS next Y12.51%ROA-1.47%Short Interest30.92MPerf YTD0.49%
Book/sh13.19P/C21.43EPS next 5Y11.62%ROE-3.02%52W High27.98 -18.73%Perf Year22.06%
Cash/sh1.06P/FCF30.52EPS past 3/5Y-ROIC3.92%52W Low18.22 24.81%Perf 3Y89.82%
Dividend Est.-EV/EBITDA19.05Sales past 3/5Y2.25% 7.57%Gross Margin52.59%Volatility3.13% 2.93%Perf 5Y-32.20%
Dividend TTM-EV/Sales2.94EPS Y/Y TTM-158.82%Oper. Margin9.20%ATR (14)0.81Perf 10Y-
Dividend Ex-Date-Quick Ratio1.09Sales Y/Y TTM13.09%Profit Margin-3.96%RSI (14)39.07Recom2.38
Dividend Gr. 3/5Y-Current Ratio2.05EPS Q/Q30.77%SMA20-4.74%Beta1.69Target Price28.00
Payout0.00%Debt/Eq0.61Sales Q/Q10.23%SMA50-6.78%Rel Volume0.77Prev Close22.86
Employees9,650LT Debt/Eq0.60EarningsNov 06SMA200-4.32%Avg Volume5.98MPrice22.74
IPO DateSep 20, 2018Option/ShortYes / YesEPS/Sales Surpr.26.30% 4.23%Net Debt/EBITDA4.38Volume4,609,566Change-0.52%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedKeybancOverweight$29$30
Jul-22-26ReiteratedMorgan StanleyEqual Weight$23$26
May-15-26ReiteratedMorgan StanleyEqual Weight$24$23
Feb-25-26ReiteratedKeybancOverweight$27$29
Feb-24-26ReiteratedLeerink PartnersOutperform$18$30
Jan-29-26ReiteratedUBSBuy$27$30
Jan-22-26UpgradePiper SandlerNeutralOverweight$12$30
Dec-18-25ReiteratedMorgan StanleyEqual Weight$37$22
Dec-08-25InitiatedBarclaysOverweight$22$30
Nov-20-25InitiatedKeyBancOverweight$27
Latest News· Times ET
Sep-15-26
Sep-13-26
Sep-11-26
Sep-10-26
Sep-04-26
Sep-01-26
Aug-31-26
Aug-28-26
Aug-26-26
Aug-19-26
Company

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue5,0204,7154,439
Cost of Goods Sold Incl. D&A2,3802,6652,530
Gross Profit2,6402,0501,909
Selling, General and Administrative Excl. Other1,5191,4301,314
Research and Development371368344
Other Operating Expense
28800
Operating Income462252251
Interest Expense259220339
Unusual Expense
Non-Operating Income (Expense)-369-256576
Net Income Before Taxes-166-224488
Income Taxes338150
Consolidated Net Income-199-232338
Net Income From Continuing Operations-199-232338
Net Income-199-232338
EPS (Recurring)-0.41-0.470.68
EPS (Basic, Before Extraordinaries)-0.41-0.470.68
EPS (Diluted)-0.40-0.470.68
EBITDA7746761,489
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio17.81
Price To Sales Ratio2.262.381.35
Gross Margin52.5943.4843.01
Operating Margin9.205.345.65
Net Margin-3.96-4.927.61
Shares Outstanding500496494
Market Capitalization11,37011,2245,982
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$28.81$24.54$20.26$15.98$11.71 Close Price0.00M0.37M0.74M1.10M1.47MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kurzius Lawrence ErikDirectorAug 20 '26Buy23.4040,000935,920188,647Aug 21
O'Neill ShivGC AND CORP SECAug 18 '26Buy23.583,99894,27387,832Aug 18
Harrington Michael JDirectorAug 12 '26Buy21.825,000109,100131,451Aug 13
VanHimbergen Robert MEVP and CFOAug 07 '26Buy23.084,20096,926137,516Aug 10
Herendeen PaulDirectorAug 07 '26Buy23.6810,000236,850111,687Aug 10
Modi Rajeev A.SEE REMARKSMay 15 '26Buy20.354,91199,939160,812May 19
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORMay 15 '26Buy20.094,97199,843171,971May 19
Kurzius Lawrence ErikDirectorDec 12 '25Buy21.3010,000213,000131,773Dec 16
Modi Rajeev A.SEE REMARKSDec 11 '25Buy21.334,50095,985123,082Dec 15
VanHimbergen Robert MEVP and CFODec 11 '25Buy21.646,950150,426124,233Dec 15
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORDec 11 '25Buy21.7522,000478,496167,000Dec 15
Kurzius Lawrence ErikDirectorMar 11 '25Buy10.2010,000102,000111,459Mar 11
Kurzius Lawrence ErikDirectorMar 07 '25Buy10.9010,000109,000101,459Mar 11
HOOVER R DAVIDDirectorMar 05 '25Buy10.9025,000272,558210,000Mar 07
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.